Menu Search
Equities

Novo Nordisk A/S

NOVO B:CPH

Novo Nordisk A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)898.20
  • Today's Change16.00 / 1.81%
  • Shares traded1.97m
  • 1 Year change+38.83%
  • Beta0.7897
Data delayed at least 15 minutes, as of Sep 19 2024 15:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy5
Outperform12
Hold9
Sell0
Strong Sell2

Share price forecast in DKK

The 26 analysts offering 12 month price targets for Novo Nordisk A/S have a median target of 1,043.00, with a high estimate of 1,200.00 and a low estimate of 560.00. The median estimate represents a 18.23% increase from the last price of 882.20.
High36.0%1,200.00
Med18.2%1,043.00
Low-36.5%560.00

Dividends in DKK

In 2023, Novo Nordisk A/S reported a dividend of 9.40 DKK, which represents a 51.61% increase over last year. The 23 analysts covering the company expect dividends of 11.17 DKK for the upcoming fiscal year, an increase of 18.84%.
Div growth (TTM)51.61%
More ▼

Earnings history & estimates in DKK

On Aug 07, 2024, Novo Nordisk A/S reported 2nd quarter 2024 earnings of 4.49 per share. This result was in line with the consensus of the 11 analysts following the company and exceeded last year's 2nd quarter results by 4.06%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate+2.20%
Novo Nordisk A/S reported annual 2023 earnings of 18.62 per share on Jan 31, 2024.
Average growth rate+23.83%
More ▼

Revenue history & estimates in DKK

Novo Nordisk A/S had 2nd quarter 2024 revenues of 68.06bn. This missed the 68.65bn consensus estimate of the 12 analysts following the company. This was 27.53% above the prior year's 2nd quarter results.
Average growth rate+5.92%
Novo Nordisk A/S had revenues for the full year 2023 of 232.26bn. This was 31.26% above the prior year's results.
Average growth rate+17.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.